Evaluating Hemadsorption Filter Use to Remove Benzodiazepines and Tricyclic Antidepressants in ICU Intoxicated Patients

What This Trial Is About

This clinical trial evaluates the use of a hemadsorption filter cytosorb4 to remove benzodiazepines or tricyclic antidepressants in patients admitted to the ICU with prolonged impaired consciousness due to intoxication. The study includes patients with neurodepressing drug intoxication who require intubation or flumazenil to prevent intubation. It aims to assess how quickly these drugs are eliminated with the hemadsorption filter and to understand the filters adsorbability and saturation timing. Participants will receive hemadsorption therapy via a dialysis catheter starting 8 hours after ICU admission if they meet specific criteria including impaired consciousness and risk factors for delayed drug elimination. Plasma drug levels will be measured frequently before and after hemadsorption initiation, including pre- and post-filter samples taken at multiple time points during the first 24 hours and daily thereafter until hemadsorption is stopped or drug levels normalize. During the study, participants will undergo sequential blood sampling to monitor drug concentrations and filter performance. Researchers will track outcomes such as time to normal drug levels, filter saturation, and complications related to catheter use or hemadsorption therapy. Additional measures include duration of mechanical ventilation, ICU stay, use of vasopressors, and overall cost effectiveness. The study duration extends through ICU discharge with safety and efficacy monitored carefully throughout treatment.

Hemadsorption to Enhance Drug Elimination in Intoxications